ALLR
NASDAQAllarity Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings1
News · 26 weeks24+100%
2025-10-262026-04-19
Mix1690d
- SEC Filings11(69%)
- Other4(25%)
- Dividends1(6%)
Latest news
25 items- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian CancerNew AACR data highlight stenoparib's potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patientsPosters now available on Allarity's website TARPON SPRINGS, Fla., April 21, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that it has published two scientific posters being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22 in San
- SECSEC Form PRE 14A filed by Allarity Therapeutics Inc.PRE 14A - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate ProgressStrengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2
- SECSEC Form 10-K filed by Allarity Therapeutics Inc.10-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and CommercializationExtends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Com
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet NeedStenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investi
- SECSEC Form S-3 filed by Allarity Therapeutics Inc.S-3 - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for EnrollmentThis is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temo
- SECSEC Form 424B5 filed by Allarity Therapeutics Inc.424B5 - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- INSIDEROfficer Graff Jeremy R. was granted 133,333 shares, increasing direct ownership by 54% to 381,644 units (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- PRAllarity Therapeutics Issues 2025 End of Year CEO Letter to ShareholdersTARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company's Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of Chief Executive Officer. Since that time, our efforts have bee
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form EFFECT filed by Allarity Therapeutics Inc.EFFECT - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form S-3 filed by Allarity Therapeutics Inc.S-3 - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form 10-Q filed by Allarity Therapeutics Inc.10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesReceived FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac
- INSIDEROfficer Graff Jeremy R. converted options into 39,494 shares and covered exercise/tax liability with 14,613 shares (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)